Eton Pharmaceuticals licenses US rights to Auson’s ASN-001 for infantile hemangiomas

Reuters2026/08/05 10:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eton Pharmaceuticals licensed U.S. rights to Auson’s late-stage ASN-001, a timolol topical gel for proliferating superficial infantile hemangiomas.
Deal expands Eton’s infantile hemangioma franchise beyond HEMANGEOL, targeting moderate cases now often treated off-label with ophthalmic timolol.
Phase II/III trial (168 patients) showed 24-week elimination or near-elimination rates of 56% (BID) and 42% (TID) vs 15% placebo.
NDA submission targeted for 2H 2027 following a bioavailability bridging study; potential U.S. launch planned for 2028.
Eton estimates 20,000 to 30,000 patients a year could be candidates, positioning ASN-001 as a potential top revenue driver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050650PRIMZONEFULLFEED9803599) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eton Pharmaceuticals licenses US rights to Auson’s ASN-001 for infantile hemangiomas

You may also like

Crypto prices